Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06514898 · ClinicalTrials.gov registry record · Phase 1
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
A Phase 1 study of Recurrent Group 3 Medulloblastoma and Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma, sponsored by University of Florida.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06514898 is a Phase 1 study of Recurrent Group 3 Medulloblastoma and Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06514898, a Phase 1 study of Recurrent Group 3 Medulloblastoma and Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study in a small number of children and young adults with relapsed/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL TTRNA-DC vaccines with GM-CSF
- BIOLOGICAL TTRNA-xALT
- DRUG Td vaccine
- BIOLOGICAL autologous HSCs
Study Locations (1)
Florida
- University of Florida Health - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06514898
The ClinicalTrials.gov registry entry for NCT06514898 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Group 3 Medulloblastoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06514898 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06514898 about?
NCT06514898 is a clinical study titled "Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma". This is a pilot study in a small number of children and young adults with relapsed/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.
What is the current status of trial NCT06514898?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-05-05. Estimated completion is 2028-12-01.
What conditions does trial NCT06514898 study?
This clinical trial studies the following conditions: Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma.
What interventions are being tested in trial NCT06514898?
The interventions under investigation include: Pembrolizumab (DRUG), TTRNA-DC vaccines with GM-CSF (BIOLOGICAL), TTRNA-xALT (BIOLOGICAL), Td vaccine (DRUG), autologous HSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT06514898?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06514898 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Recurrent Group 3 Medulloblastoma
All registered trials for this condition
Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.